Resolving the Interference of Anti‐CD38 Antibodies on Blood Compatibility Assays Using CD38 “Baitbodies” Approach Blood transfusion safety depends on swift blood compatibility testing. Alloantibodies recognizing these blood group antigens determine blood compatibility, and the transfusion of incompatible blood c...

A CD38 "baitbody" to support safe blood products for multiple myeloma patients receiving Daratumumab and Isatuximab.
onlinelibrary.wiley.com/doi/full/10....

#baitbody, #daratumumab, #felzartamab, #isatuximab, #transfusionmedicine, #antibody, #fusionprotein, #bloodcompatability, #CD38, #MM

Recent research indicates that #isatuximab monotherapy could be another safe and effective treatment option for patients with R/R #amyloidosis, with the therapy resulting in an ORR of 77%, including 57% with a VGPR or better: https://ow.ly/wbFU50XNrsR
#HemeSky

The December issue is available now! Check out the link below to read articles on #isatuximab for R/R AL #amyloidosis, ATRA-ATO combination therapy for APL, #pemigatinib for myeloid & lymphoid #neoplasms with FGFR1 rearrangements, and more: https://ow.ly/fzzm50XARLQ

Subcutaneous Isatuximab Noninferior to IV Administration in R/R MM | ASH Clinical News | American Society of Hematology

Subcutaneous #isatuximab delivered via an on-body injector was found to be noninferior to IV isatuximab plus #pomalidomide and #dexamethasone in patients with R/R #MultipleMyeloma #MMsm, with both methods resulting in comparable ORR and 12-month PFS: ow.ly/zJCh50WM6cl
#HemeSky #MyelomaSky #HemeOnc

Isatuximab Plus VRd Approved in Europe for Transplant-Eligible Newly Diagnosed Multiple Myeloma The European Commission has approved isatuximab plus VRd in transplant-eligible newly diagnosed multiple myeloma.

L'European Commission a approuvé l’ #isatuximab associé à la VRd dans le #MyélomeMultiple nouvellement diagnostiqué admissible à une greffe.
#Oncology
www.onclive.com/view/isatuxi...

Validate User

According to findings from #EHA2025, patients with newly diagnosed #MultipleMyeloma #MMsm that was treated with Isa-KRd saw increased levels of sustained MRD negativity compared with patients treated with a combination that did not include #isatuximab: ow.ly/j0cr50WjI2y
#HemeSky #HemeOnc

#Medsky🧪 #onsky #pharmasky The overall response rate was 71.1% in the on-body injector arm & 70.5% in the intravenous arm. Subcutaneous #isatuximab administered via an on-body injector appears to be as safe and effective as intravenous…

📢 Des nouvelles de l’ #EHA2025 à #Milan !

Développements dans le #MyélomeMultiple 🩸:

🔹 Progrès dans les thérapies #BCMA (ex, #Talquetamab, #CAR_T)
🔹 De l'opportunité avec l’ #Isatuximab + #CRD
🔹 Une réponse plus profonde grâce à des stratégies modernes de 1ère ligne

myelom.online/multiples-my...

2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA:

1. #Zanubrutinib
2. #Ponatinib
3. #LisoCel x2
4. #Imetelstat
5. #Epcortimab
6. #Daratumuab
7. #Axatilimab
8. #Isatuximab
9. #Asciminib
10. #ObiCel
11. #Revumenib

#HemeSky #OncSky #mmsm #leusm #MedSky #lymsm